Literature DB >> 29736834

Predicting Cholangitis with Procalcitonin: Procrastinate or Procedure?

Tilak Shah1,2, Alvin Zfass3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29736834     DOI: 10.1007/s10620-018-5098-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

1.  Emergency surgery for severe acute cholangitis. The high-risk patients.

Authors:  E C Lai; P C Tam; I A Paterson; M M Ng; S T Fan; T K Choi; J Wong
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

Review 2.  Procalcitonin Levels in Survivors and Nonsurvivors of Sepsis: Systematic Review and Meta-Analysis.

Authors:  Shubhangi Arora; Prashant Singh; Preet Mohinder Singh; Anjan Trikha
Journal:  Shock       Date:  2015-03       Impact factor: 3.454

3.  The significance of biliary pressure in cholangitis.

Authors:  T Huang; J A Bass; R D Williams
Journal:  Arch Surg       Date:  1969-05

Review 4.  Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis.

Authors:  Fumihiko Miura; Kohji Okamoto; Tadahiro Takada; Steven M Strasberg; Horacio J Asbun; Henry A Pitt; Harumi Gomi; Joseph S Solomkin; David Schlossberg; Ho-Seong Han; Myung-Hwan Kim; Tsann-Long Hwang; Miin-Fu Chen; Wayne Shih-Wei Huang; Seiki Kiriyama; Takao Itoi; O James Garden; Kui-Hin Liau; Akihiko Horiguchi; Keng-Hao Liu; Cheng-Hsi Su; Dirk J Gouma; Giulio Belli; Christos Dervenis; Palepu Jagannath; Angus C W Chan; Wan Yee Lau; Itaru Endo; Kenji Suzuki; Yoo-Seok Yoon; Eduardo de Santibañes; Mariano Eduardo Giménez; Eduard Jonas; Harjit Singh; Goro Honda; Koji Asai; Yasuhisa Mori; Keita Wada; Ryota Higuchi; Manabu Watanabe; Toshiki Rikiyama; Naohiro Sata; Nobuyasu Kano; Akiko Umezawa; Shuntaro Mukai; Hiromi Tokumura; Jiro Hata; Kazuto Kozaka; Yukio Iwashita; Taizo Hibi; Masamichi Yokoe; Taizo Kimura; Seigo Kitano; Masafumi Inomata; Koichi Hirata; Yoshinobu Sumiyama; Kazuo Inui; Masakazu Yamamoto
Journal:  J Hepatobiliary Pancreat Sci       Date:  2018-01-08       Impact factor: 7.027

5.  Procalcitonin is a useful biomarker to predict severe acute cholangitis: a single-center prospective study.

Authors:  Gyotane Umefune; Hirofumi Kogure; Tsuyoshi Hamada; Hiroyuki Isayama; Kazunaga Ishigaki; Kaoru Takagi; Dai Akiyama; Takeo Watanabe; Naminatsu Takahara; Suguru Mizuno; Saburo Matsubara; Natsuyo Yamamoto; Yousuke Nakai; Minoru Tada; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2016-10-25       Impact factor: 7.527

6.  Clinical evaluation of the Tokyo Guidelines 2013 for severity assessment of acute cholangitis.

Authors:  Takayoshi Nishino; Tetsuya Hamano; Yutaka Mitsunaga; Izumi Shirato; Miho Shirato; Tomoko Tagata; Masahiko Shimada; Shuhei Yoshida; Atsushi Mitsunaga
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-12       Impact factor: 7.027

7.  Decreasing mortality from acute biliary diseases that require endoscopic retrograde cholangiopancreatography: a nationwide cohort study.

Authors:  Paul D James; Gilaad G Kaplan; Robert P Myers; James Hubbard; Abdel Aziz Shaheen; Jill Tinmouth; Elaine Yong; Jonathan Love; Steven J Heitman
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-02       Impact factor: 11.382

8.  Analysis of risk factors predictive of early mortality and urgent ERCP in acute cholangitis.

Authors:  Jefrey Salek; Elayne Livote; Kostas Sideridis; Simmy Bank
Journal:  J Clin Gastroenterol       Date:  2009-02       Impact factor: 3.062

9.  Procalcitonin as a Decision-Supporting Marker of Urgent Biliary Decompression in Acute Cholangitis.

Authors:  Yoon Suk Lee; Kwang Bum Cho; Kyung Sik Park; Ju Yup Lee; Yoo Jin Lee
Journal:  Dig Dis Sci       Date:  2018-02-26       Impact factor: 3.199

Review 10.  Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.

Authors:  Anna Prkno; Christina Wacker; Frank M Brunkhorst; Peter Schlattmann
Journal:  Crit Care       Date:  2013-12-11       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.